[go: up one dir, main page]

BRPI0419229A - derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica - Google Patents

derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica

Info

Publication number
BRPI0419229A
BRPI0419229A BRPI0419229-0A BRPI0419229A BRPI0419229A BR PI0419229 A BRPI0419229 A BR PI0419229A BR PI0419229 A BRPI0419229 A BR PI0419229A BR PI0419229 A BRPI0419229 A BR PI0419229A
Authority
BR
Brazil
Prior art keywords
thiophenopyrimidinone
pharmaceutical composition
derivatives substituted
dehydrogenase inhibitors
steroid hormone
Prior art date
Application number
BRPI0419229-0A
Other languages
English (en)
Inventor
Lenna Hirvel
Betina Husen
Johanna Kiviniemi
Pasi Koskimies
Pekka Lehtovuori
Josef Messinger
Olli Taneli Pentikoinen
Lila Pirkkala
Pauli Saarenketo
Heinrich-Hubert Thole
Mikko Unkila
Bartholomeus Johannes Va Steen
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of BRPI0419229A publication Critical patent/BRPI0419229A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

DERIVADOS DE TIOFENOPIRIMIDINONA SUBSTITUìDOS COMO INIBIDORES DE 17BETA-HIDROXIESTERóIDE-DESI-DROGENASE, USO E COMPOSIçãO FARMACêUTICA. A presente invenção refere-se a novos derivados de tiofenopirimidinona substituidos e à sua utilização em terapia, especialmente a utilização no tratamento e/ou prevenção de uma doença ou um distúrbio dependente de hormonas esteróides, tais como doenças ou distúrbios dependentes de hormonas esteróides que requerem a inibição de enzimas 17<225>-hidroxiesteróide-desidrogenases.
BRPI0419229-0A 2004-12-13 2004-12-13 derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica BRPI0419229A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2004/053424 WO2006063615A1 (en) 2004-12-13 2004-12-13 NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17β-HYDROXYSTEROID DEHYDROGENASE

Publications (1)

Publication Number Publication Date
BRPI0419229A true BRPI0419229A (pt) 2007-12-18

Family

ID=34959788

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0419229-0A BRPI0419229A (pt) 2004-12-13 2004-12-13 derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica

Country Status (13)

Country Link
EP (1) EP1828197B1 (pt)
JP (1) JP4686549B2 (pt)
CN (1) CN101087793B (pt)
AT (1) ATE431351T1 (pt)
AU (1) AU2004325692B2 (pt)
BR (1) BRPI0419229A (pt)
CA (1) CA2590233A1 (pt)
DE (1) DE602004021145D1 (pt)
ES (1) ES2327240T3 (pt)
MX (1) MX2007007051A (pt)
NO (1) NO20073610L (pt)
PL (1) PL1828197T3 (pt)
WO (1) WO2006063615A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
TW201520219A (zh) * 2013-03-12 2015-06-01 Lilly Co Eli 咪唑並吡啶化合物
US9884839B2 (en) 2014-01-03 2018-02-06 Elexopharm Gmbh Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2
CN120114459B (zh) * 2025-05-14 2025-07-29 南京工业大学 苯并呋喃嘧啶酮或苯并噻吩嘧啶酮类化合物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054656A (en) * 1975-09-10 1977-10-18 Mead Johnson & Company Thieno[2,3-d]pyrimidine antiallergic agents
JPS62132884A (ja) * 1985-12-05 1987-06-16 Mitsubishi Chem Ind Ltd ２−ベンジルチエノ〔２，３−ｄ〕ピリミジン−４（３Ｈ）−オン誘導体
WO1989008113A1 (en) * 1988-03-02 1989-09-08 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-DIHYDROTHIENO[2,3-d]PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL APPLICATION THEREOF
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
FI20030393L (fi) * 2003-03-14 2004-09-15 Molekyyliendokrinologian Tutki Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi
US7465739B2 (en) * 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US7754709B2 (en) * 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds

Also Published As

Publication number Publication date
EP1828197B1 (en) 2009-05-13
AU2004325692A1 (en) 2006-06-22
JP2008523117A (ja) 2008-07-03
JP4686549B2 (ja) 2011-05-25
CA2590233A1 (en) 2006-06-22
MX2007007051A (es) 2007-06-26
AU2004325692B2 (en) 2012-01-19
ATE431351T1 (de) 2009-05-15
ES2327240T3 (es) 2009-10-27
WO2006063615A1 (en) 2006-06-22
NO20073610L (no) 2007-09-12
CN101087793A (zh) 2007-12-12
PL1828197T3 (pl) 2009-11-30
DE602004021145D1 (de) 2009-06-25
EP1828197A1 (en) 2007-09-05
CN101087793B (zh) 2011-09-07

Similar Documents

Publication Publication Date Title
TW200509937A (en) Novel compounds and their use in therapy
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
WO2007067504A3 (en) Lactam compounds and methods of using the same
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
SG161261A1 (en) Lactam compounds and their use as pharmaceuticals
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
MX340538B (es) Compuestos amido y sus usos como farmaceuticos.
SG163518A1 (en) Amido compounds and their use as pharmaceuticals
TW200626156A (en) Amido compounds and their use as pharmaceuticals
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
WO2008034796A3 (en) Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors
ATE520668T1 (de) Sigmarezeptor-inhibitoren
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
TW200740808A (en) Inhibiteurs de proteines kinases
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2010062506A3 (en) Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
TW200716561A (en) P38 inhibitors and methods of use thereof
NO20073610L (no) Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
WO2007108004A3 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
ATE410415T1 (de) Neue verbindungen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A E 11A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.